Trial Profile
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Apr 2024
Price :
$35
*
At a glance
- Drugs MRNA 4157 (Primary) ; Pembrolizumab (Primary)
- Indications Bladder cancer; Colon cancer; Endometrial cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Acronyms KEYNOTE-603
- Sponsors Moderna Therapeutics
- 04 Jan 2024 Planned number of patients changed from 143 to 242.
- 04 Jan 2024 Status changed from active, no longer recruiting to recruiting.
- 14 Mar 2023 According to a Moderna Therapeutics media release, data from this study will be presented at the 2023 American Association of Cancer Research (AACR) Annual Meeting (Tuesday, April 18 at 9:00 AM - 12:30 PM ET) being held in Orlando, FL.